Advertisement

Product › Details
VMX-C001 (VarmX)
![]() |
Next higher product group | coagulation factor X (recombinant) |
![]() |
Status | 2020-07-08 development existent |
![]() |
Organisation | VarmX B.V. |
Original research | Leiden University Medical Center (LUMC) | |
Record changed: 2024-11-15 |
Advertisement

More documents for VMX-C001 (VarmX)
- [1] VarmX B.V.. (11/12/24). "Press Release: VarmX Announces Appointment of John Glasspool as CEO". Leiden....
- [2] VarmX B.V.. (5/25/23). "Press Release: VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial". Leiden....
- [3] VarmX B.V.. (1/31/23). "Press Release: VarmX Appoints Paul Roos as Chief Financial Officer". Leiden....
- [4] VarmX B.V.. (7/8/20). "Press Release: VarmX Raises €32 million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants". Leiden....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top